Bio-Rad Laboratories

Bio-Rad Laboratories, founded in 1952 and headquartered in Hercules, California, is a prominent provider of innovative tools and services for the life sciences and clinical diagnostics markets. The company offers a wide range of products, including antibodies, test systems, specialized quality controls, and reagents, which are essential for research, biopharmaceutical production, and food safety testing. Bio-Rad has established a significant presence in digital PCR technology and serves over 85,000 customers globally, supported by a workforce of more than 6,500 employees. The company's sales are divided between clinical diagnostics, accounting for 56%, and life sciences, which represents 44%. Bio-Rad's operations are distributed across major markets, including the Americas, Europe, and Asia, illustrating its geographical diversity and commitment to advancing scientific research and development.

Norman D. Schwartz

CEO

23 past transactions

Afynia Laboratories

Seed Round in 2025
Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Stilla Technologies

Acquisition in 2025
Stilla Technologies is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution, the Naica System. This platform leverages advanced microfluidic technology to provide a flexible and accessible tool for high-resolution genetic analysis. By enabling compatibility with multiple chemistries and offering multiplex capabilities, Stilla Technologies aims to simplify the processes of image analysis and data exploration for researchers in various fields, including life sciences and therapeutics. The company's mission is to make digital PCR a standard tool across all areas of genetic research and application.

OncoCyte

Post in 2025
OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostic tests for cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in proprietary laboratory-developed tests, including DetermaRx for early-stage lung adenocarcinoma and DetermaIO, a gene expression-based test. Additionally, OncoCyte is advancing DetermaDx, a non-invasive blood test aimed at detecting lung cancer. The company emphasizes the importance of providing actionable information to physicians and patients during critical decision-making moments in lung cancer care. Through strategic collaborations, such as with Guardian Research Network, OncoCyte seeks to enhance patient recruitment and streamline regulatory processes, ultimately aiming to improve patient outcomes and reduce healthcare costs.

Geneoscopy

Series C in 2025
Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

OncoCyte

Post in 2024
OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostic tests for cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in proprietary laboratory-developed tests, including DetermaRx for early-stage lung adenocarcinoma and DetermaIO, a gene expression-based test. Additionally, OncoCyte is advancing DetermaDx, a non-invasive blood test aimed at detecting lung cancer. The company emphasizes the importance of providing actionable information to physicians and patients during critical decision-making moments in lung cancer care. Through strategic collaborations, such as with Guardian Research Network, OncoCyte seeks to enhance patient recruitment and streamline regulatory processes, ultimately aiming to improve patient outcomes and reduce healthcare costs.

Curiosity Diagnostics

Acquisition in 2022
Curiosity Diagnostics is a pre-commercial platform company that diagnostics PCR systems.

Dropworks

Acquisition in 2021
Dropworks, Inc., located in Phoenix, Arizona, specializes in advanced digital PCR technology known as FluxPCR, which significantly enhances the quantification of DNA and RNA in both research and clinical environments. The company employs innovative continuous flow droplet nanoreactors to streamline workflows, achieving high throughput and low costs while providing absolute quantification with ultra-high sensitivity. This technology allows for rapid assay mixing and delivers results in under 30 minutes, making it suitable for urgent diagnostic applications, including personalized medicine and cancer genotyping. Dropworks' integrated microfluidic solutions also enable the portability of digital PCR, allowing users to conduct molecular biology analyses in various settings, thus facilitating more accurate data collection and efficient treatment processes in areas such as cancer screening and viral load quantification.

Celsee Diagnostics

Acquisition in 2020
Celsee Diagnostics (formerly DeNovo Sciences) mission is to provide an easy to use platform for cancer research and diagnosis. Specifically, the company will sell an instrument system and reagent kit that allows for the separation, detection, and retrieval of circulating tumor cells (CTCs) from peripheral whole blood as an alternative to traditionally painful and invasive biopsies. Their company is developing a proprietary product that will not only allow researchers to identify and capture rare and difficult to harvest cancer cells in a microfluidic chip but also enable them to conduct downstream molecular analysis. This technology allows for the development of personalized therapies as well as the ability to monitor patient prognosis.

RainDance Technologies

Acquisition in 2017
RainDance Technologies, based in Billerica, Massachusetts, specializes in developing genomic tools for non-invasive liquid biopsy applications focused on the research, early detection, and treatment of cancer, as well as other inherited and infectious diseases. The company offers a range of innovative products, including the RainDrop digital polymerase chain reaction platform, which utilizes picoliter-sized droplets for multiplex detection of various genetic materials. Additionally, RainDance provides the ThunderStorm automated next-generation sequencing content enrichment solution, and the ThunderBolts NGS panels, designed for profiling significant cancer mutations and targeting genes associated with myeloid disorders. Through its advanced droplet technology, RainDance enables research institutions and laboratories to conduct precise genetic analysis, facilitating the understanding of complex genetic variations. Founded in 2004, the company operates as a subsidiary of Bio-Rad Laboratories and serves a global market through sales representatives and distributors.
Oxford Impedance Diagnostics Limited is a company that specializes in the research, design, and marketing of diagnostic tests aimed at measuring clinical biomarkers. Founded in 2016 and based in Oxford, United Kingdom, the company focuses on providing solutions that facilitate personalized medicine, enhance early risk detection, and support disease diagnosis and management. Its innovative products are intended to reduce healthcare costs while improving patient outcomes, contributing to more effective healthcare practices.

GnuBIO

Acquisition in 2014
GnuBIO specializes in the development of scalable DNA sequencing technology aimed at the diagnostic and applied markets. The company employs an emulsion-based microfluidic approach to create a comprehensive desktop sequencing system, enabling the analysis of single genes, gene panels, and whole genomes. GnuBIO's proprietary platform integrates all necessary steps for DNA sequencing—including target selection, enrichment, amplification, sequencing, and analysis—into a single interface and process. This innovative system significantly accelerates result delivery, shortening the time required from days to just hours, thus enhancing the efficiency of both research and clinical laboratory workflows.

AbD Serotec

Acquisition in 2013
For 30 years, AbD Serotec has been one of the world leaders in antibody production, supplying thousands of catalog antibodies, kits and accessories to scientific researchers requiring products from dendritic cell antibodies through to antibodies for microbiology. We pride ourselves on providing great customer support for all our products and services and have reliable staff on site to help with any of your antibody needs. Where are we? AbD Serotec has an ISO 9001 certified antibody production facility in Kidlington, near Oxford, UK. This facility is AbD Serotec's global headquarters, and supports our other center in Raleigh, North Carolina, USA. Our ISO 9001 certified laboratories in Puchheim, near Munich in Germany are home to our unique HuCAL custom monoclonal generation services. What can we provide for you? With antibody specialists in a range of scientific fields, AbD Serotec is able to produce and supply high quality antibodies straight to you, tailored for use with various applications including western blotting and flow cytometry. With an extensive collection of primary antibodies for studying innate immunity and having the largest range of veterinary antibodies and reagents, we empower scientists to make rewarding new discoveries. Can’t find what you need? Look no further than our custom antibody services; antibodies tailored to your needs with a wide range of antibody production and modification options. Our unique HuCAL service gives you the cutting edge of monoclonal antibody generation. A new chapter with Bio-Rad In January 2013, AbD Serotec became part of Bio-Rad Laboratories, Inc. Bio-Rad has played a leading role in the progression of scientific discovery for 60 years by providing a broad range of tools and services to the life science research and clinical diagnostics markets. With more than 7,100 employees globally, Bio-Rad are able to serve more than 100,000 research and industry customers worldwide. For more information, visit bio-rad.com. Our Mission Through innovation, 30 years of industry knowledge, and understanding our customers changing needs we will continue to build strong customer relationships and aid in advancing scientific research.
Propel Labs - Cell Sorting System Division is a automated, easy-to-use benchtop sorting flow cytometer.

QuantaLife

Acquisition in 2011
QuantaLife, Inc. was formed to develop, manufacture and market a revolutionary nucleic acid testing concept for the Life Science Research, Clinical Molecular Diagnostics, Personalized Medical Care and Industrial markets. Our suite of products, which are based on our proprietary nucleic acid testing method, will enable rapid detection and quantification of nucleic acids in complex samples on a flexible, automated instrument. This technology provides an order of magnitude improvement in performance over current platforms at a fraction of the cost. QuantaLife is a small biotechnology startup involved in the early development phases of the technology.

Biotest - Businesses

Acquisition in 2009
Biotest - Businesses provides pharmaceutical, biotherapeutic, and diagnostic products.

DiaMed Holding AG

Acquisition in 2007
DiaMed develops, manufactures and markets a complete line of reagents and instruments used in blood typing and screening.

Blackhawk Biosystems

Acquisition in 2006
Blackhawk is a manufacturer of quality control products for use in laboratories that perform infectious disease testing procedures.

Ciphergen Biosystems

Funding Round in 2006
Ciphergen Biosystems, Inc. is focused on the discovery, development and commercialization of high-value, molecular diagnostic products to improve patient care. Ciphergen, along with its prestigious scientific collaborators, has ongoing diagnostic programs primarily in oncology with an initial focus in ovarian and prostate cancer. Based in Fremont, California

Ciphergen Biosystems - ProteinChip Systems Business

Acquisition in 2006
Ciphergen Biosystems - ProteinChip Systems Business is a Enhanced Laser Desorption/ Ionization.

MJ GeneWorks

Acquisition in 2004
MJ Research, Inc. is a biotechnology company specializing in premium instruments and consumables used in modern biological research. MJ Research pioneered the use of Peltier-effect technology and has introduced a number of other innovations in the thermal-cycling field. MJ Research employs approximately 300 employees.

Quantase Ltd.

Acquisition in 2002
Quantase Ltd. is a company specializing in newborn screening diagnostic products.

Helix Diagnostics

Acquisition in 2001
Helix Diagnostics is specializing in the development and manufacture of test kits for autoimmune disease.

Bio-Rad Pasteur

Acquisition in 1999
Bio-Rad Pasteur is a manufacturer and distributor of life science research and clinical diagnostics products. Bio-Rad Pasteur was formerly known as Pasteur Sanofi-Diagnostics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.